TABLE 2.

Comparison of SUV_max of ⁶⁸Ga-NC-BCH with ¹⁸F-FDG in Metastases

Patient no.	Tumor type	CLDN18.2 expression	Time between prior anti-CLDN18.2 therapy and experiment (mo)	Prior therapy lines	Gastrectomy	Metastatic lesion	68Ga-NC-BCH	18F-FDG
1	Gastric cancer	90%, 3+	—	3	Yes	Peritoneum	5	4.7
						Bone	9.7	19.8
						Liver	7.6	18.9
						Lymph node	7.1	10.9
2	Gastric cancer	80%, 3+	—	3	No	Lymph node	Negative	8.9
3	Gastric cancer	40%, 2+	—	3	No	Peritoneum	2.5	2
						Lymph node	18.6	4.7
4	Colorectal cancer	40%, 3+	—	3	No	Peritoneum	3.1	2.1
						Lymph node	5.1	1.7
5	Gastric cancer	90%, 3+	—	3	No	—	Negative	Negative
6	Gastric cancer	50%, 2+	10.5	3	Yes	Anastomosis	4.2	7.7
						Lymph node	2.2	9.1
						Peritoneum	2.1	10.1
						Subcutaneous tissue	1.5	5.7
7	Gastric cancer	90%, 3+	3	3	No	Lymph node	6.5	Negative
						Abdominal wall	2.3	1.7
						Peritoneum	4.1	1.7
8	Gastric cancer	90%, 3+	—	3	No	Peritoneum	4.2	Negative
						Bone	2.3	8
						Ovary	2.0	1.8
9	Gastric cancer	40%, 2+	5.5	3	Yes	Peritoneum	4.9	1
						Subcutaneous tissue	6.6	2.1
						Pleura	3.2	Negative
10	Gastric cancer	90%, 3+	15	2	Yes	Peritoneum	4.7	1.8
						Lymph node	10.1	1.6
						Muscle	2.0	Negative
11	Gastric cancer	60%, 2+	6.5	3	No	Peritoneum	3	3
						Lymph node	2.1	1.9